Copyright
©2012 Baishideng Publishing Group Co.
World J Gastrointest Endosc. Apr 16, 2012; 4(4): 108-116
Published online Apr 16, 2012. doi: 10.4253/wjge.v4.i4.108
Published online Apr 16, 2012. doi: 10.4253/wjge.v4.i4.108
Table 2 Summary of the main differences in the recommendations for colorectal cancer surveillance programs in inflammatory bowel disease patients
Guidelines | Remission | Beginning of surveillance | Surveillance schedule | Random biopsy protocol | New endoscopic technique recommended |
U.K. 2002[7] | Necessary | 8-10 yr (pancolitis) | 3 yr (2° decade) | Recommended | Not mentioned |
15-20 yr (left-sided colitis) | 2 yr (3° decade) | ||||
1 yr (4° decade) | |||||
AGA 2003[8] | Not mentioned | 8 yr (pancolitis) | Every 1-2 yr | Recommended | Not mentioned |
15 yr (left-sided colitis) | |||||
ACG 2004[5] | Necessary | 8-10 yr | Every 1-2 yr | Recommended | Not mentioned |
ECCO 2008[4] | Necessary | 8 yr (pancolitis) | 2 yr (1°-2° decade) | Recommended | Chromoendoscopy |
15 yr (left-sided colitis) | - 1 yr (3° decade) | ||||
BSG 2010[6] | Necessary | 10 yr | - 3 yr lower risk | Recommended | Chromoendoscopy |
- 2 yr intermediate risk | |||||
- 1 yr higher risk |
- Citation: Guagnozzi D, Lucendo AJ. Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? World J Gastrointest Endosc 2012; 4(4): 108-116
- URL: https://www.wjgnet.com/1948-5190/full/v4/i4/108.htm
- DOI: https://dx.doi.org/10.4253/wjge.v4.i4.108